ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1036

Effects of Three Potential Anabolic Disease-Modifying Osteoarthritis Drugs – Sprifermin, Insulin-like Growth Factor 1 and Bone Morphogenetic Protein 7 – on Matrix Production and the Phenotype of Articular Chondrocytes

Sylvia Muller, Martin Michaelis, Sven Lindemann and Anne Gigout, Merck KGaA, Darmstadt, Germany

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: chondrocytes, Disease-modifying antirheumatic drugs, growth factors and osteoarthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, October 22, 2018

Title: Osteoarthritis and Joint Biology – Basic Science Poster I

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Disease-modifying osteoarthritis drugs with an anabolic mode of action should stimulate the growth of new hyaline cartilage. For instance, recombinant human fibroblast growth factor 18 (FGF18; sprifermin) has been shown to increase cartilage volume in knee OA patients. In vitro studies have also shown that sprifermin stimulates proliferation and the production of hyaline cartilage matrix molecules in articular chondrocytes. Other growth factors, such as insulin-like growth factor 1 (IGF1) and bone morphogenetic protein 7 (BMP7), also exert an anabolic effect on cartilage or cartilage cells in vitro and in vivo. How these three growth factors compare with each other is unknown. The aim of this study was to differentiate the effects of sprifermin, IGF1 and BMP7 on matrix production and cell phenotype in articular chondrocytes.

Methods: Primary bovine chondrocytes were cultured as 3D scaffold-free constructs for 4 weeks with sprifermin 100 ng/mL, IGF1 100 ng/mL or BMP7 300 ng/mL with permanent or cyclic exposure (24h at the beginning of each week) or left untreated (control). Two experiments were made: sprifermin versus IGF1 and sprifermin versus BMP7. At the end of the culture, the 3D constructs were harvested for biochemical (glycosaminoglycan or GAG and hydroxyproline or HPro) and gene expression analysis (N=3-4).

Results: As previously shown, cyclic exposure to sprifermin increased the GAG and HPro content of the 3D constructs while permanent exposure had a lower effect on GAG production and no effect on HPro (Figs. 1 and 2). Similarly, expression of col2a1 (type II collagen) and acan (aggrecan) increased with cyclic exposure. Furthermore, sprifermin reduced col1a2 (type I collagen) expression and had no effect on hypertrophy markers.

IGF1 increased extracellular matrix (ECM) production (GAG and HPro content, Fig. 1) as well as expression of col2a1 and acan, but only with permanent exposure. Col1a2 expression was increased with permanent exposure. Similarly, BMP7 increased ECM production but also increased col1a2 expression (with cyclic exposure) and hypertrophy marker expression.

Conclusion: A similar stimulation of cartilage ECM molecule expression in chondrocytes was obtained with permanent exposure to IGF1, permanent or cyclic exposure to BMP7 and cyclic exposure to sprifermin. However, sprifermin was the only growth factor that both influenced the chondrocytes towards the production of hyaline cartilage and prevented two unwanted phenomena: production of fibrous cartilage (containing type I collagen) and cartilage hypertrophy.

 


Disclosure: S. Muller, Merck KGaA, 3; M. Michaelis, Merck KGaA, 3; S. Lindemann, Merck KGaA, 3; A. Gigout, Merck KGaA, 3.

To cite this abstract in AMA style:

Muller S, Michaelis M, Lindemann S, Gigout A. Effects of Three Potential Anabolic Disease-Modifying Osteoarthritis Drugs – Sprifermin, Insulin-like Growth Factor 1 and Bone Morphogenetic Protein 7 – on Matrix Production and the Phenotype of Articular Chondrocytes [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/effects-of-three-potential-anabolic-disease-modifying-osteoarthritis-drugs-sprifermin-insulin-like-growth-factor-1-and-bone-morphogenetic-protein-7-on-matrix-production-and-the-phenotype-of/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/effects-of-three-potential-anabolic-disease-modifying-osteoarthritis-drugs-sprifermin-insulin-like-growth-factor-1-and-bone-morphogenetic-protein-7-on-matrix-production-and-the-phenotype-of/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology